Literature DB >> 30193111

A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.

Leeat Keren1, Marc Bosse1, Diana Marquez1, Roshan Angoshtari1, Samir Jain1, Sushama Varma1, Soo-Ryum Yang1, Allison Kurian1, David Van Valen2, Robert West1, Sean C Bendall3, Michael Angelo4.   

Abstract

The immune system is critical in modulating cancer progression, but knowledge of immune composition, phenotype, and interactions with tumor is limited. We used multiplexed ion beam imaging by time-of-flight (MIBI-TOF) to simultaneously quantify in situ expression of 36 proteins covering identity, function, and immune regulation at sub-cellular resolution in 41 triple-negative breast cancer patients. Multi-step processing, including deep-learning-based segmentation, revealed variability in the composition of tumor-immune populations across individuals, reconciled by overall immune infiltration and enriched co-occurrence of immune subpopulations and checkpoint expression. Spatial enrichment analysis showed immune mixed and compartmentalized tumors, coinciding with expression of PD1, PD-L1, and IDO in a cell-type- and location-specific manner. Ordered immune structures along the tumor-immune border were associated with compartmentalization and linked to survival. These data demonstrate organization in the tumor-immune microenvironment that is structured in cellular composition, spatial arrangement, and regulatory-protein expression and provide a framework to apply multiplexed imaging to immune oncology.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast Cancer; Checkpoint; Imaging; MIBI; Mass spectrometry; Multiplexed Ion Beam Imaging; Proteomics; Systems Biology; Tumor Immunology; Tumor Microenvironment

Mesh:

Substances:

Year:  2018        PMID: 30193111      PMCID: PMC6132072          DOI: 10.1016/j.cell.2018.08.039

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  51 in total

1.  Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer.

Authors:  Joe Yeong; Aye Aye Thike; Jeffrey Chun Tatt Lim; Bernett Lee; Huihua Li; Siew-Cheng Wong; Susan Swee Shan Hue; Puay Hoon Tan; Jabed Iqbal
Journal:  Breast Cancer Res Treat       Date:  2017-02-23       Impact factor: 4.872

2.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

Review 3.  Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.

Authors:  Maryann J Kwa; Sylvia Adams
Journal:  Cancer       Date:  2018-02-09       Impact factor: 6.860

Review 4.  Biomarkers of response to PD-1/PD-L1 inhibition.

Authors:  Saman Maleki Vareki; Carmen Garrigós; Ignacio Duran
Journal:  Crit Rev Oncol Hematol       Date:  2017-06-09       Impact factor: 6.312

5.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Authors:  Kei Muro; Hyun Cheol Chung; Veena Shankaran; Ravit Geva; Daniel Catenacci; Shilpa Gupta; Joseph Paul Eder; Talia Golan; Dung T Le; Barbara Burtness; Autumn J McRee; Chia-Chi Lin; Kumudu Pathiraja; Jared Lunceford; Kenneth Emancipator; Jonathan Juco; Minori Koshiji; Yung-Jue Bang
Journal:  Lancet Oncol       Date:  2016-05-03       Impact factor: 41.316

6.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

7.  Multiplexed ion beam imaging of human breast tumors.

Authors:  Michael Angelo; Sean C Bendall; Rachel Finck; Matthew B Hale; Chuck Hitzman; Alexander D Borowsky; Richard M Levenson; John B Lowe; Scot D Liu; Shuchun Zhao; Yasodha Natkunam; Garry P Nolan
Journal:  Nat Med       Date:  2014-03-02       Impact factor: 53.440

8.  A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays.

Authors:  Wei Huang; Kenneth Hennrick; Sally Drew
Journal:  Hum Pathol       Date:  2012-08-31       Impact factor: 3.466

9.  Deep Learning Automates the Quantitative Analysis of Individual Cells in Live-Cell Imaging Experiments.

Authors:  David A Van Valen; Takamasa Kudo; Keara M Lane; Derek N Macklin; Nicolas T Quach; Mialy M DeFelice; Inbal Maayan; Yu Tanouchi; Euan A Ashley; Markus W Covert
Journal:  PLoS Comput Biol       Date:  2016-11-04       Impact factor: 4.475

Review 10.  Combination immunotherapy: a road map.

Authors:  Patrick A Ott; F Stephen Hodi; Howard L Kaufman; Jon M Wigginton; Jedd D Wolchok
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

View more
  231 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 2.  Genetic and non-genetic clonal diversity in cancer evolution.

Authors:  James R M Black; Nicholas McGranahan
Journal:  Nat Rev Cancer       Date:  2021-03-16       Impact factor: 60.716

Review 3.  A Cancer Biologist's Primer on Machine Learning Applications in High-Dimensional Cytometry.

Authors:  Timothy J Keyes; Pablo Domizi; Yu-Chen Lo; Garry P Nolan; Kara L Davis
Journal:  Cytometry A       Date:  2020-06-30       Impact factor: 4.355

4.  Comprehensive Integration of Single-Cell Data.

Authors:  Tim Stuart; Andrew Butler; Paul Hoffman; Christoph Hafemeister; Efthymia Papalexi; William M Mauck; Yuhan Hao; Marlon Stoeckius; Peter Smibert; Rahul Satija
Journal:  Cell       Date:  2019-06-06       Impact factor: 41.582

5.  Biological explorations with nanoscale secondary ion mass spectrometry.

Authors:  Frank Gyngard; Matthew L Steinhauser
Journal:  J Anal At Spectrom       Date:  2019-07-10       Impact factor: 4.023

Review 6.  Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics.

Authors:  Mayar Allam; Shuangyi Cai; Ahmet F Coskun
Journal:  NPJ Precis Oncol       Date:  2020-05-01

7.  Geostatistical visualization of ecological interactions in tumors.

Authors:  Hunter Bryan Boyce; Parag Mallick
Journal:  Proceedings (IEEE Int Conf Bioinformatics Biomed)       Date:  2020-02-06

Review 8.  Studying interactions between dendritic cells and T cells in vivo.

Authors:  Aleksey Chudnovskiy; Giulia Pasqual; Gabriel D Victora
Journal:  Curr Opin Immunol       Date:  2019-03-15       Impact factor: 7.486

9.  Decoding the Body Language of Immunity: Tackling the Immune System at the Organism Level.

Authors:  Nicolas Chevrier
Journal:  Curr Opin Syst Biol       Date:  2019-11-06

Review 10.  Tumour heterogeneity and the evolutionary trade-offs of cancer.

Authors:  Jean Hausser; Uri Alon
Journal:  Nat Rev Cancer       Date:  2020-02-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.